SCHEMBL3654292

SCHEMBL3654292

c1ccc2cc(-c3ccnc4c3nc(-c3ccsc3)n4C3CCNCC3)ccc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 1/20 0.36
CSNK1D P48730 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
KDM1A O60341 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
MAPK10 P53779 2/20 0.34
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
PRKCZ Q05513 2/20 0.33
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
GSK3B P49841 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
TP53 P04637 1/20 0.32
PDGFRB P09619 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3646647 0.90 NR1H4 (0.41) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D
SCHEMBL3647836 0.88 MAPK11 (0.41) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D
SCHEMBL3646892 0.88 NR1H4 (0.40) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D
SCHEMBL3653517 0.86 NR1H4 (0.39) NR1H4SLC6A2SLC6A4SLC6A3MAPK14
SCHEMBL3653798 0.86 MAPK10 (0.38) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D
SCHEMBL3653383 0.85 MAPK14 (0.41) NR1H4CSNK1DMAPK11MAPK14MAPK9
SCHEMBL3650998 0.85 NR1H4 (0.38) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D
SCHEMBL3648574 0.85 NR1H4 (0.38) NR1H4SLC6A2SLC6A4SLC6A3MAPK14
SCHEMBL3652977 0.85 NR1H4 (0.38) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D
SCHEMBL4167558 0.85 PLAUR (0.39) NR1H4SLC6A2SLC6A4SLC6A3CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185556-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM Wyeth a Corporation of the State of Delaware (US) 2010-05-19 EP claimed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US claimed
WO-2009029609-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-05 WO claimed
EP-2185556-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM Wyeth a Corporation of the State of Delaware (US) 2010-05-19 EP disclosed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US disclosed
WO-2009029609-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WNT1, CTNNB1, WNT3A NR1H4 374/4885SLC6A2 2043/4885SLC6A4 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.